Cellectar Biosc (CLRB) Stock Price, Quote & News

Company Profile

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort,...

Industry: Biotechnology

Sector: Healthcare

Phone: 608 441 8120

Website: www.cellectar.com

Address:

100 Campus Drive, Florham Park, United States

thedavidsonny May. 12 at 7:19 PM

$CLRB $GCTK $XXII $AREB $FRGT CLRB EARNINGS COMING ON THE 14TH BUY NOW WHILE IT'S CHEAP!!! PT $11 💰 🤑 💸 💲 🪙 💶 💰 🤑 💸 💲

1 · Reply

tommy_john May. 12 at 7:06 PM

$AREB $CLRB $FRGT $GCTK $XXII FRGT goes 200% mark it

0 · Reply

ALLEGEDLY01 May. 12 at 6:45 PM

$CLRB $GCTK $XXII $AREB $FRGT Which one goes 100% first?

0 · Reply

Crocodile100 May. 12 at 6:22 PM

$CLRB sssssibal

0 · Reply

TRstocktwits2024 May. 12 at 3:00 PM

$CLRB THIS STOCK IS A FKG JOKE. FKING CRIMINALS

1 · Reply

EvenBetter99 May. 12 at 9:23 AM

$CLRB Post-FDA approval Cellectar Biosciences becomes an absolute goldmine for Big Pharma targeting an explosive buyout valued between $1.5 billion and $3.5+ billion! This massive de-risking unlocks unprecedented values matching historic radiopharma acquisitions and rockets the share price to a breathtaking $35 to $100+ range. By capturing a total monopoly in the multi-billion-dollar blood cancer market with zero competition, CLRB stands as the ultimate crown jewel asset destined for a legendary, hyper-premium mega-acquisition. 🚀🚀🚀🚀🚀🚀🚀🚀

0 · Reply

EvenBetter99 May. 12 at 9:10 AM

$CLRB CLRB is a coiled spring set for an unprecedented, explosive rocket ride to the moon! 100% Clinical Success: Lead drug Iopofosine I-131 boasts an incredible 100% response rate in Waldenstrom’s macroglobulinemia patients. This virtually guarantees a blockbuster FDA approval. Monopoly Market Power: It holds exclusive Orphan Drug Designation. This grants zero competition and massive pricing power across the US and Europe. Wall Street Euphoria: Top analysts label it a goldmine, screaming a strong buy with a $11.00+ price target. This signals an imminent 250%+ surge. And just starting. Trillion-Dollar Tech: Their revolutionary PLE platform alters global oncology, making CLRB the ultimate buyout target for Big Pharma.💪💪💪💪💪💪💪

0 · Reply

thedavidsonny May. 12 at 3:58 AM

$CLRB 🔥 🔥 🔥 🔥 🔥 Better buy ASAP!!! THEY KNOW EARINGS ARE GONNA BE GREAT. REMEMBER PT $11

0 · Reply

CEOBuysDisclosures May. 12 at 2:10 AM

$CLRB CEO purchased 8,680 shares at $2.88 for a total of $24,998. CARUSO JAMES V now owns 20,318 shares. https://ceo-buys.com

0 · Reply

islandpunk May. 12 at 12:12 AM

$CLRB 2 insider purchases just reported as well. https://www.sec.gov/Archives/edgar/data/1202770/000110465926058851/xslF345X06/tm2614289-1_4seq1.xmlhttps://www.sec.gov/Archives/edgar/data/1279704/000110465926058854/xslF345X06/tm2614289-2_4seq1.xml

0 · Reply

Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026

2026-05-05T14:55:41.000Z - 7 days ago

Cellectar Biosciences price target lowered to $11 from $14 at Roth Capital

2026-05-05T13:23:40.000Z - 8 days ago

Cellectar Biosciences reports CLOVER WaM trial achieves primary endpoint

May 5, 2026, 7:10 AM EDT - 8 days ago

Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia

May 5, 2026, 7:00 AM EDT - 8 days ago

Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million

2026-04-14T13:28:41.000Z - 4 weeks ago

Cellectar Biosciences enrolls first patient in CLR 121125 trial

$Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)$

Apr 14, 2026, 8:35 AM EDT - 4 weeks ago

Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)

2026-03-10T11:45:55.000Z - 2 months ago

Cellectar Biosciences upgraded to Buy from Hold at Maxim

2026-03-04T14:50:33.000Z - 2 months ago

Cellectar Biosciences price target lowered to $14 from $18 at Roth Capital

Mar 4, 2026, 8:30 AM EST - 2 months ago

Cellectar Biosciences Earnings Call Transcript: Q4 2025

2026-03-04T12:16:54.000Z - 2 months ago

Cellectar Biosciences reports FY25 EPS ($8.35) vs ($41.89) last year

Mar 4, 2026, 7:15 AM EST - 2 months ago

Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates

Feb 25, 2026, 8:05 AM EST - 2 months ago

Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026

2026-02-17T13:25:24.000Z - 3 months ago

Cellectar Biosciences expands global intellectual property estate

Feb 17, 2026, 8:05 AM EST - 3 months ago

Cellectar Biosciences Expands Global Intellectual Property Estate

Jan 14, 2026, 4:30 PM EST - 4 months ago

Cellectar Biosciences Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 4:30 PM EST - 4 months ago

Cellectar Biosciences Transcript: Biotech Showcase 2026

2026-01-09T13:16:25.000Z - 4 months ago

Cellectar Biosciences to highlight company’s 2026 strategic initiatives

Jan 9, 2026, 8:05 AM EST - 4 months ago

Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference

2025-12-16T13:11:21.000Z - 5 months ago

Cellectar Biosciences announces supply agreement with Ionetix

Dec 16, 2025, 8:05 AM EST - 5 months ago

Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies

Nov 13, 2025, 8:30 AM EST - 6 months ago

Cellectar Biosciences Earnings Call Transcript: Q3 2025

2025-11-13T12:25:57.000Z - 6 months ago

Cellectar Biosciences reports Q3 EPS ($1.41), consensus ($2.53)

Nov 13, 2025, 7:20 AM EST - 6 months ago

Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update

2025-10-27T12:42:21.000Z - 7 months ago

Cellectar Biosciences receives RPDD from U.S. FDA for iopofosine I 131

2025-10-20T21:30:12.000Z - 7 months ago

Cellectar Biosciences files to sell 2.1M shares of common stock for holders

2025-10-14T12:36:26.000Z - 7 months ago

Cellectar Biosciences presents posters at AACR on CLR 121225, CLR 225

Oct 14, 2025, 8:30 AM EDT - 7 months ago

Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research

2025-10-07T12:50:46.000Z - 7 months ago

Cellectar Biosciences enters agreements to raise $5.8M

2025-10-06T13:55:27.000Z - 7 months ago

EMA news ‘a substantial positive catalyst’ for Cellectar, says Oppenheimer

2025-10-06T11:10:58.000Z - 7 months ago

Cellectar says EMA confirms eligibility to file for CMA for iopofosine I 131

2025-09-30T12:55:26.000Z - 8 months ago

Cellectar Biosciences says Iopofosine I 131 well tolerated in case studies

2025-09-24T12:40:14.000Z - 8 months ago

Cellectar, Evestia entered into agreement for Phase 1b study of CLR 125

2025-09-11T12:10:32.000Z - 8 months ago

Cellectar Biosciences, ITM enter supply agreement for GMP-grade Ac-225

Sep 11, 2025, 8:05 AM EDT - 8 months ago

Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225

Sep 9, 2025, 8:05 AM EDT - 8 months ago

Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit

Sep 5, 2025, 8:45 AM EDT - 8 months ago

Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September

Sep 3, 2025, 8:05 AM EDT - 9 months ago

Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research

Aug 27, 2025, 8:05 AM EDT - 9 months ago

Cellectar Biosciences to Present Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer

Aug 14, 2025, 8:30 AM EDT - 9 months ago

Cellectar Biosciences Earnings Call Transcript: Q2 2025

Aug 14, 2025, 7:19 AM EDT - 9 months ago

Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Aug 7, 2025, 8:05 AM EDT - 9 months ago

Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025

Jul 2, 2025, 4:15 PM EDT - 11 months ago

Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option

Jul 1, 2025, 9:25 AM EDT - 11 months ago

Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering

Jun 26, 2025, 8:05 AM EDT - 11 months ago

Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement

Jun 24, 2025, 8:30 AM EDT - 11 months ago

Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC)

Jun 18, 2025, 4:30 PM EDT - 11 months ago

Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split

$Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma$

Jun 11, 2025, 8:05 AM EDT - 1 year ago

Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma

Jun 5, 2025, 9:00 AM EDT - 1 year ago

Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules

Jun 4, 2025, 8:05 AM EDT - 1 year ago

Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)

May 13, 2025, 8:30 AM EDT - 1 year ago

Cellectar Biosciences Earnings Call Transcript: Q1 2025

May 13, 2025, 7:05 AM EDT - 1 year ago

Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update

May 7, 2025, 8:05 AM EDT - 1 year ago

Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025

Apr 30, 2025, 8:05 AM EDT - 1 year ago

Cellectar Announces Plan to Explore Strategic Alternatives

Mar 13, 2025, 8:30 AM EDT - 1 year ago

Cellectar Biosciences Earnings Call Transcript: Q4 2024

Mar 13, 2025, 7:05 AM EDT - 1 year ago

Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update

Mar 5, 2025, 8:05 AM EST - 1 year ago

Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025

Feb 12, 2025, 12:00 PM EST - 1 year ago

Cellectar Biosciences Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 5, 2025, 8:05 AM EST - 1 year ago

Cellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 14, 2025, 2:30 PM EST - 1 year ago

Cellectar Biosciences Transcript: Biotech Showcase 2025

Jan 12, 2025, 6:00 PM EST - 1 year ago

Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare Conference

Dec 10, 2024, 5:00 PM EST - 1 year ago

Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring

Nov 21, 2024, 8:00 AM EST - 1 year ago

NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225)

Nov 18, 2024, 8:30 AM EST - 1 year ago

Cellectar Biosciences Earnings Call Transcript: Q3 2024

Nov 18, 2024, 7:05 AM EST - 1 year ago

Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update

Nov 14, 2024, 8:05 AM EST - 1 year ago

Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225

Nov 12, 2024, 8:05 AM EST - 1 year ago

Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer

Nov 11, 2024, 4:05 PM EST - 1 year ago

Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024

Nov 7, 2024, 6:40 AM EST - 1 year ago

Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024

Nov 1, 2024, 5:00 PM EDT - 1 year ago

Cellectar Biosciences Announces Compliance Regarding Filing of Form 10-Q

Aug 26, 2024, 6:40 AM EDT - 1 year ago

Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom's Macroglobulinemia

Aug 23, 2024, 5:00 PM EDT - 1 year ago

Cellectar to Restate Previously Issued Financial Statements – Company Announces Receipt of Expected Delinquency Notification Letter from Nasdaq

Aug 13, 2024, 8:30 AM EDT - 1 year ago

Cellectar Biosciences Earnings Call Transcript: Q2 2024

Aug 13, 2024, 6:40 AM EDT - 1 year ago

Cellectar Biosciences Reports Financial Results for Q2 2024 and Provides a Corporate Update

Aug 8, 2024, 5:15 PM EDT - 1 year ago

UPDATE -- Cellectar Biosciences to Announce Second Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024

Jul 24, 2024, 8:00 AM EDT - 1 year ago

Cellectar Biosciences Transcript: Study Update

Jul 23, 2024, 6:40 AM EDT - 1 year ago

Cellectar Biosciences' Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom's Macroglobulinemia Pivotal Study with 78% of Major Response Patients Remaining Progression Free at 18 Months

Jul 22, 2024, 6:40 AM EDT - 1 year ago

Cellectar Biosciences Announces Exercise of Tranche B Warrants and Purchase of New Warrants for Approximately $19.4 million with the Potential to Raise Up to an Additional $73.3 Million

Jun 27, 2024, 6:40 AM EDT - 2 years ago

Cellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results from Its CLOVER WaM Pivotal Trial and Waldenstrom's Macroglobulinemia Market Landscape

May 29, 2024, 6:40 AM EDT - 2 years ago

Cellectar Biosciences and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis Fungoides

May 14, 2024, 8:30 AM EDT - 2 years ago

Cellectar Biosciences Earnings Call Transcript: Q1 2024

May 14, 2024, 6:40 AM EDT - 2 years ago

Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update

thedavidsonny May. 12 at 7:19 PM

$CLRB $GCTK $XXII $AREB $FRGT CLRB EARNINGS COMING ON THE 14TH BUY NOW WHILE IT'S CHEAP!!! PT $11 💰 🤑 💸 💲 🪙 💶 💰 🤑 💸 💲

1 · Reply

tommy_john May. 12 at 7:06 PM

$AREB $CLRB $FRGT $GCTK $XXII FRGT goes 200% mark it

0 · Reply

ALLEGEDLY01 May. 12 at 6:45 PM

$CLRB $GCTK $XXII $AREB $FRGT Which one goes 100% first?

0 · Reply

Crocodile100 May. 12 at 6:22 PM

$CLRB sssssibal

0 · Reply

TRstocktwits2024 May. 12 at 3:00 PM

$CLRB THIS STOCK IS A FKG JOKE. FKING CRIMINALS

1 · Reply

EvenBetter99 May. 12 at 9:23 AM

0 · Reply

EvenBetter99 May. 12 at 9:10 AM

0 · Reply

thedavidsonny May. 12 at 3:58 AM

$CLRB 🔥 🔥 🔥 🔥 🔥 Better buy ASAP!!! THEY KNOW EARINGS ARE GONNA BE GREAT. REMEMBER PT $11

0 · Reply

CEOBuysDisclosures May. 12 at 2:10 AM

$CLRB CEO purchased 8,680 shares at $2.88 for a total of $24,998. CARUSO JAMES V now owns 20,318 shares. https://ceo-buys.com

0 · Reply

islandpunk May. 12 at 12:12 AM

0 · Reply

islandpunk May. 11 at 11:22 PM

$CLRB Stonepine Capital Management filed 13G for 9.99%. https://www.sec.gov/Archives/edgar/data/1279704/000093583626000240/xslSCHEDULE_13G_X02/primary_doc.xml

2 · Reply

TRstocktwits2024 May. 11 at 10:17 PM

$CLRB MMs trying to get you to sell with these after hours small orders

0 · Reply

thedavidsonny May. 11 at 6:16 PM

$CLRB 🔥 🔥 🔥 🔥 🔥 Load up !!!

0 · Reply

IAmMsMoneyMaker May. 11 at 2:20 PM

$CLNN & $CLRB HUGE UPSIDE FOR BOTH!!!🥳 🚀 🚀 🚀 🚀

0 · Reply

EvenBetter99 May. 11 at 12:35 PM

$CLRB only up here 🚀🚀🚀🚀🚀🚀

1 · Reply

revuelto May. 11 at 11:31 AM

$CLRB classic biotech lull until at least q4 for any ‘major’ stock moving catalysts i.e. p3 initiation, then the nda filing….welcome to range bound trading…checking out of this board for now…see you in a few quarters or sooner if a bp partnership lands 😀🥳

0 · Reply

Samishere May. 11 at 12:51 AM

$CHRS $CLRB Wow! Now even Jackass_Dumb is a bear on this garbage! He now doesn’t expect it to even hit $2.20 this year ! Two biggest pumps have given up! Maybe it is time to go long after all 🤪🤣🤪🤣🤪🤣

0 · Reply

WatchAndTrip May. 10 at 10:51 PM

$CLRB ….hanging on till shorts cover

1 · Reply

Samishere May. 10 at 4:06 PM

$CHRS $CLRB Even neofraud is over this smelly 💩 He/she/ they/them use to post pump lies 5-10 times a day! Now hardly one a week! Thats your short sell indicator right there 🤪🤣🤪

0 · Reply

thedavidsonny May. 10 at 1:01 AM

$CLRB Monday should be interesting... IMO a surge before Earnings

1 · Reply

Joby099 May. 9 at 3:00 AM

$CLRB

0 · Reply

thedavidsonny May. 8 at 10:49 PM

$CLRB 🔥 🔥 🔥 🔥 TIME TO FLY BOYS!!!!

0 · Reply

Market Cap	16.84M
Revenue (ttm)	0.00
Net Income (ttm)	-44.58M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	3,765,327
Avg Vol	14,877,256
Day's Range	N/A - N/A
Shares Out	46.08M
Stochastic %K	31%
Beta	0.52
Analysts	Sell
Price Target	$4.00